Matrix metalloproteinase 9 may be involved in contraction of vascular smooth muscle cells in an in vitro rat model of subarachnoid hemorrhage

Dang,Baoqi; Shen,Haitao; Li,Haiying; Zhu,Min; Guo,Chunhua; He,Weichun

doi:10.3892/mmr.2016.5736

Matrix metalloproteinase 9 may be involved in contraction of vascular smooth muscle cells in an in vitro rat model of subarachnoid hemorrhage

Authors:
- Baoqi Dang
- Haitao Shen
- Haiying Li
- Min Zhu
- Chunhua Guo
- Weichun He
View Affiliations

Affiliations: Department of Neurosurgery, Zhangjiagang Hospital of Traditional Chinese Medicine, Nanjing University of Chinese Medicine, Suzhou, Jiangsu 215600, P.R. China, Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China
Published online on: September 13, 2016 https://doi.org/10.3892/mmr.2016.5736
Pages: 4279-4284

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Our previous study determined that prominent cerebral vasospasm (CVS) may occur in an in vivo model of subarachnoid hemorrhage (SAH) in rats. Matrix metalloproteinase 9 (MMP‑9) expression levels in basilar arteries were upregulated in a similar manner to the development of CVS following SAH. To identify the changes that occur in the contractility of cerebrovascular smooth muscle cells and the expression levels of MMP‑9 in an in vitro model of SAH, rat cerebrovascular smooth muscle cells were isolated, cultured, and then stimulated with hemolysate. Additionally, 2-[(4-phenoxyphenylsulfonyl)methyl]thiirane (SB-3CT), a selective MMP-9 inhibitor, was used to determine the effect of MMP‑9 on the contractility of cerebrovascular smooth muscle cells. Cerebrovascular smooth muscle cells were successfully isolated and cultured in vitro, and hemolysate stimulation enhanced their contractility and increased MMP‑9 expression levels. The present study also revealed that pretreatment with SB‑3CT decreased MMP‑9 expression levels in cerebrovascular smooth muscle cells, and reduced their contractility upon hemolysate treatment. Therefore, the current study confirmed that MMP‑9 is important for the enhancement of the contractility of cerebrovascular smooth muscle cells in an in vitro rat model of SAH.

View Figures

View References

1	Baggott CD and Aagaard-Kienitz B: Cerebral vasospasm. Neurosurg Clin N Am. 25:497–528. 2014. View Article : Google Scholar : PubMed/NCBI
2	Nishizawa S and Laher I: Signaling mechanisms in cerebral vasospasm. Trends Cardiovasc Med. 15:24–34. 2005. View Article : Google Scholar : PubMed/NCBI
3	Pluta RM: Delayed cerebral vasospasm and nitric oxide: Review, new hypothesis and proposed treatment. Pharmacol Ther. 105:23–56. 2005. View Article : Google Scholar : PubMed/NCBI
4	Sehba FA and Bederson JB: Mechanisms of acute brain injury after subarachnoid hemorrhage. Neurol Res. 28:381–398. 2006. View Article : Google Scholar : PubMed/NCBI
5	Suhardja A: Mechanisms of disease: Roles of nitric oxide and endothelin-1 in delayed cerebral vasospasm produced by aneurysmal subarachnoid hemorrhage. Nat Clin Pract Cardiovasc Med. 1:110–116; quiz 2 p following 116. 2004. View Article : Google Scholar : PubMed/NCBI
6	Cunningham LA, Wetzel M and Rosenberg GA: Multiple roles for MMPs and TIMPs in cerebral ischemia. Glia. 50:329–339. 2005. View Article : Google Scholar : PubMed/NCBI
7	Fatar M, Stroick M, Griebe M and Hennerici M: Matrix metalloproteinases in cerebrovascular diseases. Cerebrovasc Dis. 20:141–151. 2005. View Article : Google Scholar : PubMed/NCBI
8	Rosenberg GA: Matrix metalloproteinases in neuroinflammation. Glia. 39:279–291. 2002. View Article : Google Scholar : PubMed/NCBI
9	Wang Z, Fang Q, Dang BQ, Shen XM, Shu Z, Zuo G, He WC and Chen G: Potential contribution of matrix metalloproteinase-9 (mmp-9) to cerebral vasospasm after experimental subarachnoid hemorrhage in rats. Ann Clin Lab Sci. 42:14–20. 2012.PubMed/NCBI
10	Choudhri TF, Hoh BL, Solomon RA, Connolly ES Jr and Pinsky DJ: Use of a spectrophotometric hemoglobin assay to objectively quantify intracerebral hemorrhage in mice. Stroke. 28:2296–2302. 1997. View Article : Google Scholar : PubMed/NCBI
11	Humphrey JD, Baek S and Niklason LE: Biochemomechanics of cerebral vasospasm and its resolution: I. A new hypothesis and theoretical framework. Ann Biomed Eng. 35:1485–1497. 2007. View Article : Google Scholar : PubMed/NCBI
12	Kim JH, Yi HJ, Ko Y, Kim YS, Kim DW and Kim JM: Effectiveness of papaverine cisternal irrigation for cerebral vasospasm after aneurysmal subarachnoid hemorrhage and measurement of biomarkers. Neurol Sci. 35:715–722. 2014. View Article : Google Scholar : PubMed/NCBI
13	Kasuya H, Onda H, Takeshita M, Okada Y and Hori T: Efficacy and safety of nicardipine prolonged-release implants for preventing vasospasm in humans. Stroke. 33:1011–1015. 2002. View Article : Google Scholar : PubMed/NCBI
14	Nishiguchi M, Ono S, Iseda K, Manabe H, Hishikawa T and Date I: Effect of vasodilation by milrinone, a phosphodiesterase III inhibitor, on vasospastic arteries after a subarachnoid hemorrhage in vitro and in vivo: Effectiveness of cisternal injection of milrinone. Neurosurgery. 66:158–164; discussion 164. 2010. View Article : Google Scholar : PubMed/NCBI
15	Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, Vajkoczy P, Wanke I, Bach D, Frey A, et al: Randomized trial of clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling. Stroke. 43:1463–1469. 2012. View Article : Google Scholar : PubMed/NCBI
16	Zhang Y, Clark JF, Pyne-Geithman G and Caruso J: Metallomics study in CSF for putative biomarkers to predict cerebral vasospasm. Metallomics. 2:628–637. 2010. View Article : Google Scholar : PubMed/NCBI
17	Horstmann S, Su Y, Koziol J, Meyding-Lamadé U, Nagel S and Wagner S: MMP-2 and MMP-9 levels in peripheral blood after subarachnoid hemorrhage. J Neurol Sci. 251:82–86. 2006. View Article : Google Scholar : PubMed/NCBI
18	Rosell A, Ortega-Aznar A, Alvarez-Sabín J, Fernández-Cadenas I, Ribó M, Molina CA, Lo EH and Montaner J: Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke. 37:1399–1406. 2006. View Article : Google Scholar : PubMed/NCBI
19	Sarrafzadeh A, Copin JC, Bengualid DJ, Turck N, Vajkoczy P, Bijlenga P, Schaller K and Gasche Y: Matrix metalloproteinase-9 concentration in the cerebral extracellular fluid of patients during the acute phase of aneurysmal subarachnoid hemorrhage. Neurol Res. 34:455–461. 2012. View Article : Google Scholar : PubMed/NCBI
20	Chou SH, Feske SK, Simmons SL, Konigsberg RG, Orzell SC, Marckmann A, Bourget G, Bauer DJ, De Jager PL, Du R, et al: Elevated peripheral neutrophils and matrix metalloproteinase 9 as biomarkers of functional outcome following subarachnoid hemorrhage. Transl Stroke Res. 2:600–607. 2011. View Article : Google Scholar : PubMed/NCBI
21	McGirt MJ, Lynch JR, Blessing R, Warner DS, Friedman AH and Laskowitz DT: Serum von Willebrand factor, matrix metalloproteinase-9, and vascular endothelial growth factor levels predict the onset of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Neurosurgery. 51:1128–1134; discussion 1134–1135. 2002. View Article : Google Scholar : PubMed/NCBI